title: Substance P binding sites on intestinal lymphoid aggregates and blood vessels in inflammatory bowel disease correspond to authentic NK-1 receptors.
abstract: Previous reports have described the ectopic expression of substance P binding sites on lymphoid aggregates and small blood vessels in inflammatory bowel disease. In this report, three non-peptide NK-1 receptor antagonists, CP-96,345, RP-67,580, and L-703,606 abolished saturable 125I-Bolton-Hunter substance P binding to the ectopically expressed receptors in frozen sections of surgically resected bowel from five patients with either Crohn's disease or ulcerative colitis. The rank order of affinity was approximately substance P approximately CP-96,345 approximately L-703,606 > RP-67,580. These results suggest that: (i) the ectopically expressed substance P binding sites in inflammatory bowel disease are authentic NK-1 receptors, (ii) all ectopically expressed receptors on small blood vessels, and lymphoid aggregates as well as normally expressed receptors on the bowel circular muscle have similar receptor affinities and specificities for substance P and the non-peptide antagonists, and (iii) non-peptide antagonists may be therapeutically beneficial in inflammatory bowel disease by inhibiting the pro-inflammatory effects of substance P acting via the NK-1 receptor.
authors.affiliation: Department of Surgery, Duke University Medical Center, Durham, NC 27710.
authors.forename: C R
authors.initials: CR
authors.lastname: Mantyh
authors.forename: S R
authors.initials: SR
authors.lastname: Vigna
authors.forename: J E
authors.initials: JE
authors.lastname: Maggio
authors.forename: P W
authors.initials: PW
authors.lastname: Mantyh
authors.forename: R R
authors.initials: RR
authors.lastname: Bollinger
authors.forename: T N
authors.initials: TN
authors.lastname: Pappas
mesh_terms: D001665:Binding Sites; D001713:Biphenyl Compounds / Q000494:pharmacology; D001808:Blood Vessels / Q000378:metabolism; D006801:Humans; D007211:Indoles / Q000494:pharmacology; D015212:Inflammatory Bowel Diseases / Q000378:metabolism*; D007413:Intestinal Mucosa / Q000378:metabolism*; D007422:Intestines / Q000098:blood supply*; D054833:Isoindoles; D008221:Lymphoid Tissue / Q000378:metabolism*; D064729:Neurokinin-1 Receptor Antagonists; D011812:Quinuclidines / Q000494:pharmacology; D018040:Receptors, Neurokinin-1 / Q000378:metabolism*; D013373:Substance P / Q000037:antagonists & inhibitors / Q000378:metabolism*
chemical_list: D001713:Biphenyl Compounds; D007211:Indoles; D054833:Isoindoles; D064729:Neurokinin-1 Receptor Antagonists; D011812:Quinuclidines; D018040:Receptors, Neurokinin-1; C071693:7,7-diphenyl-2-(1-imino-2-(2-methoxyphenyl)ethyl)perhydroisoindol-4-one; C076851:L 703606; D013373:Substance P; C066892:CP 96345